The aim is to design and industrialize new pharmacological in vitro assays for the screening of compounds/biopharmaceuticals in 3D, combining microfluidics, BioMEMS systems and BIOMIMESYS®. The idea is to allow the development of more complex and relevant cellular structures for predictive therapeutical screens (e.g. reconstitution of a tumor and its vascularization for anti-cancer drugs), in a format allowing a higher throughput than existing systems.
What we bring to the partnership
These devices will include our 3D cell culture hydroscaffold™ BIOMIMESYS®, as a biomimetic material for mimicking the extracellular matrix.
List of partners
- SMMiL-E team : Seeding Microsystems in Medecine in Lille – European-Japanese Technologies against Cancer, CNRS UMI-2820 LIMMS/IIS
- Institut d’Electronique, de Micro-Electronique et de Nanotechnologie (IEMN)
- HCS Pharma